Budget impact analysis of pemetrexed introduction: Case study from a teaching hospital perspective, Thailand

Journal of the Medical Association of Thailand

Volumn 94, Issue 9, 2011, Pages 1026-1034

  Chanjaruporn, Farsai ^a   Roughead, Elizabeth E ^b   Sooksriwong, Cha oncin ^a   Kaojarern, Sming ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Budget impact analysis; Pemetrexed; Pharmaceutical subsidization; Teaching hospital

Indexed keywords

DOCETAXEL; PEMETREXED;

ANALYTIC METHOD; ARTICLE; BUDGET; BUDGET IMPACT ANALYSIS; CANCER INCIDENCE; CANCER PATIENT; DRUG COST; DRUG FORMULARY; GOVERNMENT; HEALTH CARE COST; HEALTH CARE PLANNING; HOSPITAL FINANCE; HUMAN; LONG TERM CARE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; TEACHING HOSPITAL; THAILAND;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BUDGETS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GLUTAMATES; GUANINE; HEALTH CARE COSTS; HOSPITALS, TEACHING; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MODELS, ECONOMIC; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THAILAND;

EID: 80053063394     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. World Health Organization. Fact sheet no. 297: Cancer [database on the Internet]. 2010 [cited 2010 Oct 12]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/index.html
2. World Health Organization. Are the number of cancer cases increasing or decreasing in the world? [database on the Internet] 2008 [cited 2010 Oct 12]. Available from: http://www.who.int/features/qa/15/en/index.html
3. Ministry of Public Health. Thailand health profile. Bangkok: The War Veterans Organization of Thailand; 2008
4. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97
5. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C. Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 2009; 66: 141-9
6. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-41
7. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small- cell lung cancer. N Engl J Med 2002; 346: 92-8
8. Center for Drug Evaluation and Research US Food and Drug Administration. Pescribing information for Alimta (Pemetrexed for injection) [database on the Internet]. 2004 [cited 2010 Feb 14]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021677lbl.pdf
9. Eli Lilly and Company. Highlights of prescribing information for Alimta [database on the Internet]. 2004 [cited 2010 Feb 14]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf
10. Chang J, Sung J. Health plan budget impact analysis for pimecrolimus. J Manag Care Pharm 2005; 11: 66-73
11. Smith DG, Cerulli A, Frech FH. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Clin Ther 2005; 27: 951-9
12. Danese MD, Reyes C, Northridge K, Lubeck D, Lin CY, O'Connor P. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clin Ther 2008; 30: 775-84
13. Kasemsup V, Prakongsai P, Tangcharoensathien V. Budget impact analysis of a policy on universal access to RRT under universal coverage in Thailand. J Nephrol Soc Thai 2006; 12:136-48
14. Kanavos P. Policy approaches to pharmaceutical pricing and reimbursement in European countries. London: London School of Economics and Political Science; 2006
15. Patented Medicine Prices Review Board, Canada. Budget impact analysis guidelines: needs assessment. Analytical study series [database on the Internet]. 2007 [cited 2009 Jan 20]. Available from: http://www.pmprb-cepmb.gc.ca/CMFiles/BIA-may0738LVV-5282007-5906.pdf
16. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmaco-economics 2001; 19: 609-21
17. Leelahavarong P, Chaikledkaew U, Hongeng S, Kasemsup V, Lubell Y, Teerawattananon Y. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. BMC Health Serv Res 2010; 10: 209
18. Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3) [database on the Internet]. 2008 [cited 2010 Mar 4]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/content/AECB791C29482920CA25724400188EDB/$File/PBAC4.3.2.pdf
19. World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th revision version for 2007 [database on the Internet]. 2007 [cited 2009 Jan 27]. Available from: http://apps.who.int/classifications/apps/icd/icd10online/
20. The Australian Institute of Health and Welfare. Cancer incidence data cubes [database on the Internet]. 2010 [cited 2010 Mar 18]; Available from: http://www.aihw.gov.au/cancer-incidence-data-cubes/http://www.aihw.gov.au/cancer/data/datacubes/index.cfm
21. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology for non-small cell lung cancer v.2.2010 [database on the Internet]. 2010 [cited 2010 Feb 15]; Available from: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
22. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-66
23. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098
24. th December 2007; Jainad Narendhorn meeting room, Food and Drug Administration, Ministry of Public Health Thailand; 2007